Scholar Rock Holding Corporation (SRRK)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
39.60 USD
-0.92
(-2.270%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 39.60 |
Hot Take ↕ | Oct. 10, 2026, 3:38 a.m. EDT
The investment case for Scholar Rock is currently paralyzed by a stark disconnect between its aggressive analyst targets and its deteriorating financial reality. While the company boasts a 'strong buy' recommendation and a mean target price significantly higher than the current trading level, the underlying business is bleeding cash, posting negative free cash flow, and carrying substantial debt against a shrinking book value. The market's recent reaction to earnings—despite a reported surge—has been muted, likely because investors are wary of the path to profitability in a capital-intensive biotech environment. Technically, the stock is struggling, trading well below its 50-day moving average and showing a consistent downward drift over the last two weeks. This weakness is reinforced by the options market, which is crowded with protective put buyers, indicating that retail and institutional traders are hedging against further declines rather than chasing the upside. With no dividend to provide income and a balance sheet that requires constant capital raising to sustain operations, the risk-reward profile remains skewed toward caution until the company can demonstrate a clear, sustained path to positive cash flow. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.099044 |
| AutoETS | 0.099407 |
| AutoARIMA | 0.099410 |
| MSTL | 0.103339 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 1.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.262 |
| Excess Kurtosis | -1.20 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 80.318 |
| Market Cap | 4,822,696,960 |
| Forward P/E | -15.69 |
| Beta | 0.62 |
| Website | https://www.scholarrock.com |
As of Oct. 10, 2026, 3:38 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly in the near term where out-of-the-money puts dominate open interest. While there is some call activity at strikes above the current price, the significant concentration of put open interest at lower strikes suggests a fear of downside volatility rather than a bullish bet on a rapid rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.25061727 |
| Address1 | 301 Binney Street |
| Address2 | 3rd Floor |
| All Time High | 70.0 |
| All Time Low | 4.325 |
| Ask | 52.74 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,765,130 |
| Average Daily Volume3 Month | 1,533,876 |
| Average Volume | 1,533,876 |
| Average Volume10Days | 1,765,130 |
| Beta | 0.623 |
| Bid | 40.68 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | 2.087 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 39.6 |
| Current Ratio | 7.021 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 40.91 |
| Day Low | 39.2 |
| Debt To Equity | 80.318 |
| Display Name | Scholar Rock |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,017,600 |
| Earnings Call Timestamp Start | 1,786,017,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -404,883,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.476 |
| Enterprise Value | 4,646,484,480 |
| Eps Current Year | -3.21644 |
| Eps Forward | -2.52421 |
| Eps Trailing Twelve Months | -3.32 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 51.2548 |
| Fifty Day Average Change | -11.6548 |
| Fifty Day Average Change Percent | -0.22738945 |
| Fifty Two Week Change Percent | 25.061726 |
| Fifty Two Week High | 61.76 |
| Fifty Two Week High Change | -22.16 |
| Fifty Two Week High Change Percent | -0.3588083 |
| Fifty Two Week Low | 27.07 |
| Fifty Two Week Low Change | 12.529999 |
| Fifty Two Week Low Change Percent | 0.462874 |
| Fifty Two Week Range | 27.07 - 61.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,527,255,000,000 |
| Float Shares | 104,088,663 |
| Forward Eps | -2.52421 |
| Forward P E | -15.688076 |
| Free Cashflow | -153,875,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 289 |
| Fullday Change | -0.920002 |
| Fullday Change Percent | -2.2704885 |
| Fullday Price | 39.6 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -207,408,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00728 |
| Held Percent Institutions | 1.1757 |
| Implied Shares Outstanding | 121,785,282 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Scholar Rock Holding Corporation |
| Market | us_market |
| Market Cap | 4,822,696,960 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_548810128 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -408,591,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,070,996,307 |
| Number Of Analyst Opinions | 16 |
| Open | 40.27 |
| Operating Cashflow | -296,827,008 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Phone | 857 259 3860 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 39.6 |
| Post Market Time | 1,792,008,043 |
| Previous Close | 40.52 |
| Price Eps Current Year | -12.3117485 |
| Price Hint | 2 |
| Price To Book | 18.974606 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.839 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | -0.920002 |
| Regular Market Change Percent | -2.2704887 |
| Regular Market Day High | 40.91 |
| Regular Market Day Low | 39.2 |
| Regular Market Day Range | 39.2 - 40.91 |
| Regular Market Open | 40.27 |
| Regular Market Previous Close | 40.52 |
| Regular Market Price | 39.6 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 1,277,743 |
| Return On Assets | -0.58819 |
| Return On Equity | -1.67773 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 121,785,282 |
| Shares Percent Shares Out | 0.1866 |
| Shares Short | 22,722,119 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 18,008,058 |
| Short Name | Scholar Rock Holding Corporatio |
| Short Percent Of Float | 0.23290001 |
| Short Ratio | 10.74 |
| Source Interval | 15 |
| State | MA |
| Symbol | SRRK |
| Target High Price | 84.0 |
| Target Low Price | 58.0 |
| Target Mean Price | 70.4375 |
| Target Median Price | 71.5 |
| Total Cash | 492,088,000 |
| Total Cash Per Share | 4.041 |
| Total Debt | 203,832,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.32 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 48.3186 |
| Two Hundred Day Average Change | -8.718601 |
| Two Hundred Day Average Change Percent | -0.18043986 |
| Type Disp | Equity |
| Volume | 1,277,743 |
| Website | https://www.scholarrock.com |
| Zip | 2,142 |